Immunic Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
/ 
Frequently asked questions
To buy Immunic Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Immunic Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Immunic Inc. is IMUX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Immunic Inc. has its primary listing on NASDAQ. You can trade Immunic Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Immunic Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Immunic Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Immunic Inc..